Irons Brian K, Snella Kathleen A, McCall Kenneth, MacLaughlin Eric J, Villarreal Maumi
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Am J Health Syst Pharm. 2002 Sep 1;59(17):1615-25. doi: 10.1093/ajhp/59.17.1615.
The third edition of guidelines from the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III]) is discussed. The most recent classifications for low-density-lipoprotein (LDL) cholesterol, high-density-lipoprotein (HDL), total cholesterol, and triglycerides are provided. LDL cholesterol goals, cardiovascular risk assessment, therapeutic goals, and pharmacologic treatment options are discussed for both primary and secondary prevention of cardiovascular disease. In addition, the management of dyslipidemia in patients with diabetes and metobolic syndrome is addressed, and the differences between the old and new guidelines are highlighted. The ATP III guidelines may help health care professionals to better screen and categorize patients on the basis of their coronary heart disease (CHD) risk. The updated guidelines recommend more intensive lipid-lowering treatments for primary prevention in patients with two or more risk factors.
本文讨论了美国国家胆固醇教育计划成人高血胆固醇检测、评估和治疗专家小组(成人治疗小组III [ATP III])发布的第三版指南。文中提供了低密度脂蛋白(LDL)胆固醇、高密度脂蛋白(HDL)、总胆固醇和甘油三酯的最新分类。针对心血管疾病的一级和二级预防,讨论了LDL胆固醇目标、心血管风险评估、治疗目标以及药物治疗选择。此外,还探讨了糖尿病和代谢综合征患者血脂异常的管理,并强调了新旧指南之间的差异。ATP III指南可能有助于医疗保健专业人员根据患者的冠心病(CHD)风险更好地进行筛查和分类。更新后的指南建议对具有两个或更多风险因素的患者进行更强化的降脂治疗以进行一级预防。